Aquestive Therapeutics, Inc. AQST

Company Overview

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing orally administered and other non-invasive therapies using proprietary drug delivery technologies. The company operates primarily in the biotechnology and pharmaceutical industries, with a focus on central nervous system disorders, allergy and anaphylaxis treatment, and complex molecule delivery systems. Its principal revenue drivers include licensed pharmaceutical products, proprietary therapies, manufacturing and supply agreements, and collaborative development partnerships. Public filings and investor disclosures identify the company’s core technology platform as thin-film oral delivery systems designed to improve administration, bioavailability, and patient adherence.

The company’s principal business lines include development of proprietary products such as epinephrine and seizure-related therapies, as well as manufacture of licensed products for pharmaceutical partners. Aquestive’s key markets include patients with epilepsy, severe allergic reactions, and other conditions requiring rapid or convenient drug administration. The company traces its origins to MonoSol Rx, founded in 2004, which specialized in oral soluble film technologies. It later evolved through acquisitions and restructuring into Aquestive Therapeutics and became publicly traded on NASDAQ under the ticker AQST in 2018. The company positions itself through proprietary formulation expertise, intellectual property related to film-based drug delivery, and specialized manufacturing capabilities.